Dementia with Lewy bodies: Review and pharmacotherapeutic implications

Pharmacotherapy

Volumn 19, Issue 7, 1999, Pages 795-803

  Rojas Fernandez, Carlos H ^a   MacKnight, Chris ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DEBRISOQUINE 4 HYDROXYLASE; DONEPEZIL; DOPAMINE; FLUOXETINE; HALOPERIDOL; LEVODOPA; MOCLOBEMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUINIDINE; RECEPTOR; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

BEHAVIOR DISORDER; CLINICAL FEATURE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOPAMINERGIC NERVE CELL; HALLUCINATION; HUMAN; LEWY BODY; NEUROCHEMISTRY; NEUROPATHOLOGY; PREVALENCE; REVIEW; SEROTONINERGIC SYSTEM; SOMNOLENCE;

DEMENTIA; HUMANS; LEWY BODIES;

EID: 0032885118     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.10.795.31555     Document Type: Review

References (58)

1. Pryse-Phillips W, Galasko D. Non-Alzheimer dementias. In: Gauthier S, ed. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz, 1996:51-69.
2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
3. Rockwood K, Howard K, MacKnight C, Darvesh S. Spectrum of disease in vascular cognitive impairment. Neuroepidemiology 1999 In press.
4. Kalra S, Bergeron C, Lang AE. Lewy body disease and dementia. Arch Intern Med 1996;156:487-93.
5. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
6. Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990;40:1523-8.
7. McKeith IG, Fairbaim A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-8.
8. McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia [letter]. Lancet 1995;346:699.
9. Organizing Committee, Canadian Consensus Conference on the Assessment of Dementia. Assessing dementia: the Canadian consensus. Can Med Assoc J 1991;144:851-3.
10. Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs Aging 1997;10(5):367-83.
11. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997;48:376-80.
12. Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997;62:243-52.
13. Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998:51:351-7.
14. Ballard C, Patel A, Oyebode F, Wilcock G. Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Age Ageing 1996;25:209-13.
15. Del-Ser T, Munoz DG, Hachinski V. Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Neurology 1996;46:682-6.
16. Herrmann N, Lanctot KL. From transmitters to treatment: the pharmacotherapy of behavioral disturbances in dementia. Can J Psychiatry 1997;42(suppl 1):51S-64.
17. Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging 1998;12(2):115-27.
18. McKeith IG, Fairbaim AF, Perry EK, et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22(4):911-22.
19. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia [letter]. Lancet 1995;346:185.
20. Ballard C, Grace J, McKeith IG, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease [letter]. Lancet 1998;351:1032-3.
21. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989;321(5):303-9.
22. Feely J, Coakley D. Altered pharmacodynamics in the elderly. Clin Geriatr Med 1990;6(2):269-83.
23. 2 receptors in demented patients with severe neuroleptic sensitivity [letter]. Lancet 1994;343(8904): 1044-5.
24. Perry EK, McKeith IG, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 1991;640:197-202.
25. Perry EK, Marshall E, Perry RH, et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord 1990;4:87-95.
26. Piggott MA, Perry EK, Marshall EF, et al. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biol Psychiatry 1998;44:765-74.
27. Gordon J, Rojas-Fernandez C, Rockwood K. Practical solutions to polypharmacy problems in the elderly. Can J Diagn 1998;15(4):78-90.
28. LeCouter DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34(5):359-73.
29. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998;35(1):49-64.
30. Pollock BG, Mulsant BH. Antipsychotics in older patients. A safety perspective. Drugs Aging 1995;6(4):312-23.
31. Von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug metabolism in old age. Principles and problems of assessment. In: Bloom FE, Kupfer DJ, eds. Pyschopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1461-9.
32. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-9.
33. Mayerson MB. Special pharmacokinetic considerations in the elderly. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992:9-1-9-43.
34. Relling MV, Evans WE. Genetic polymorphisms of drug metabolism. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992:7-1-7-32.
35. Shulman RW, Ozdemir V. Psychotropic medications and cytochrome P450-2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 1997;42(suppl 1):4S-9.
36. Mungall D, White R. Aging and warfarin therapy [letter]. Ann Intern Med 1992;117(10):878-9.
37. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolamin the elderly. N Engl J Med 1991;324:1691-8.
38. Hoffmann DW, Winter MST, Bartels S, et al. Therapeutic dose:serum level relationships of risperidone and active metabolite in a geriatric population [letter]. Psychopharmacol Bull 1995;37(3):525.
39. Preskom SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects of oxidative drug metabolism. Clin Pharmacokinet 1997;32(suppl 1):1-21.
40. Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-8.
41. 2 dopamine occupancy in the human living brain. A PET study with risperidone. Psychopharmacology 1993;110:265-72.
42. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
43. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry 1998;59(suppl 1):5-10.
44. Raskind MA. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. J Clin Psychiatry 1998;59(suppl 9):28-32.
45. Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 1997;48(suppl 6):S17-24.
46. Raskind MA. Alzheimer's disease. Treatment of noncognitive behavioral abnormalities. In: Bloom FE, Kupfer DJ, eds. Pyschopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1427-35.
47. Lanctot KL, Hermann N, Eryavec G, et al. Central serotonergic (5-HT) function is related to agitated aggression in Alzheimer's disease [abstr]. Clin Pharmacol Ther 1998;63(2):222.
48. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders, Drugs Aging 1994;4(4):331-55.
49. Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53(4):608-36.
50. 3 receptor antagonist. Neurology 1995;45:1305-8.
51. Levy R, Eagger S, Griffiths M, et al. Lewy bodies and response to tacrine in Alzheimer's disease [letter]. Lancet 1994;343;176.
52. Lebert F, Pasquier F, Souliez L, Petit H. Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:516-19.
53. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229-38.
54. Kaufer DI, Catt KE, Lopez OL, DeKosky ST. Dementia with Lewy bodies: response of delirium-like features to donepezil [letter]. Neurology 1998;51:1512.
55. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:877-83.
56. Geizer M, Ancill RJ. Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry 1998;43:421-2.
57. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
58. Lovestone S, Graham N, Howard R. Guidelines on drug treatment for Alzheimer's disease. Lancet 1997;350:232-3.